Tampa General Hospital is Only Florida Hospital Participating in Clinical Trial of New Treatment for Urinary Incontinence Post-Prostate Removal

Study Evaluates New Device Designed to Reduce Post‑Prostatectomy Incontinence.

Tampa, FL (April 14 2026) —Tampa General Hospital (TGH) and the USF Health Morsani College of Medicine are leading the way in urological research. The TGH Urology Institute has enrolled its first patient in the ARID II pivotal clinical trial. This national study will evaluate the Voro Urologic Scaffold, an investigational device intended to support urinary control in men following prostate removal surgery. The study is led locally by Dr. Trushar Patel, urologist with the TGH Urology Institute and associate professor of Medicine with the USF Health Morsani College of Medicine, and director of Urologic Oncology and Robotic Surgery with USF Health. TGH is the only site in Florida and one of only 19 hospitals in the country participating in the trial.

Developed by Levee Medical, the Voro Urologic Scaffold is placed during prostatectomy and is designed to reinforce the urinary sphincter, the muscle responsible for continence. The scaffold is made from a resorbable material similar to surgical sutures and is engineered to provide structural support for up to nine months before dissolving. The goal is to promote healing during the early recovery period without leaving a permanent implant.

“Post‑operative incontinence is one of the most challenging issues patients face after prostate surgery,” Patel said. “Participating in this pivotal study allows us to evaluate a promising technology that may help men regain urinary control sooner and improve their quality of life.”

The ARID II study will enroll 266 participants in as many as 30 sites across the United States. Participants are randomly assigned to receive the investigational device or standard care and will be followed for up to two years to assess safety and effectiveness.

Urinary incontinence is a common complication after prostate removal. Research shows that about two‑thirds of men continue to experience leakage at six months, and nearly one‑third report symptoms one year after surgery. The Voro Urologic Scaffold is intended to address this need during the critical early healing phase.

The Voro Urologic Scaffold is limited to investigational use and is not approved for commercial use in the United States or any other country.